Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Kruewel, Thomas ^a,e   Schenone, Silvia ^b   Radi, Marco ^c   Maga, Giovanni ^d   Rohrbeck, Astrid ^a,e   Botta, Maurizio ^c   Borlak, Juergen ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d CNR   (Italy)

^e FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 2 PHENYLETHYL) 6 METHYL 1,5 DIHYDRO 4H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 1 (2 HYDROXY 2 PHENYLETHYL) 6 THIOXO 1,5,6,7 TETRAHYDRO 4H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 4 CHLORO (2 CHLORO 2 PHENYLETHYL) 6 METHYL 1H PYRAZOLO[3,4 D]PYRIMIDINE; 6(ALKYLTHIO) 1 (2 HYDROXY 2 PHENYLETHYL) 1,5 DIHYDRO 4H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 6(ALKYLTHIO) 4 CHLORO 1 (2 CHLORO 2 PHENYLETHYL) 1H PYRAZOLO[3,4 D]PYRIMIDINE; ABELSON KINASE; CASPASE 3; CASPASE 7; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; DISCS LARGE HOMOLOG 7; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GENE PRODUCT; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NESTIN; PODOPLANIN; PROTEIN C FOS; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; THY 1 ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE C SRC; PROTEIN-TYROSINE KINASE C-SRC; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG TUMOR; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; PATHOLOGY; SYNTHESIS;

MURINAE;

ANIMALS; BLOTTING, WESTERN; CACO-2 CELLS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HEP G2 CELLS; HUMANS; MICE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78649767861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014143     Document Type: Article

References (92)

1. Sirvent A, Benistant C, Roche S (2008) Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100: 617-631.
2. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480.
3. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
4. Oetzel C, Jonuleit T, Gotz A, van der KH, Michels H, et al. (2000) The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 6: 1958-1968.
5. Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18 Suppl 6: vi42-vi46.
6. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
7. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, et al. (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103: 16870-16875.
8. Martinelli G, Soverini S, Rosti G, Baccarani M (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 19: 1872-1879.
9. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283: 143-151.
10. Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
11. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, et al. (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116: 1582-1591.
12. Saad F (2009) Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 103: 434-440.
13. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, et al. (2010) Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 28: 1387-1394.
14. Saad F, Lipton A (2009) SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36: 177-184.
15. Yardley DA, Burris HA, III, Markus T, Spigel DR, Greco FA, et al. (2009) Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 9: 237-242.
16. Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, et al. (2008) Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 27: 7212-7222.
17. Huynh H (2010) Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 15: 13-26.
18. Zhu AX, Duda DG, Sahani DV, Jain RK (2009) Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 15: 263-268.
19. Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112: 250-259.
20. Yau T, Chan P, Epstein R, Poon RT (2009) Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29: 10-17.
21. Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, et al. (2004) Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem 47: 1595-1598.
22. Carraro F, Naldini A, Pucci A, Locatelli GA, Maga G, et al. (2006) Pyrazolo[3,4- d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 49: 1549-1561.
23. Schenone S, Brullo C, Bruno O, Bondavalli F, Mosti L, et al. (2008) Synthesis, biological evaluation and docking studies of 4-amino substituted 1Hpyrazolo[ 3,4-d]pyrimidines. Eur J Med Chem 43: 2665-2676.
24. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, et al. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 50: 5579-5588.
25. Reamon-Buettner SM, Borlak J (2008) Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer Res 68: 7587-7596.
26. Reamon-Buettner SM, Borlak J (2008) Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer Res 68: 7587-7596.
27. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932.
28. Johnson DG, Walker CL (1999) Cyclins and cell cycle checkpoints. Annu Rev of Pharmacol and Toxicol 39: 295-312.
29. Payton M, Chung G, Yakowec P, Wong A, Powers D, et al. (2006) Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66: 4299-4308.
30. Roche S, Fumagalli S, Courtneidge SA (1995) Requirement for Src Family Protein-Tyrosine Kinases in G(2) for Fibroblast Cell-Division. Science 269: 1567-1569.
31. Adolph D, Flach N, Mueller K, Ostareck DH, Ostareck-Lederer A (2007) Deciphering the cross talk between hnRNP K and c-Src: the c-Src activation domain in hnRNP K is distinct from a second interaction site. Mol Cell Biol 27: 1758-1770.
32. Ostareck-Lederer A, Ostareck DH, Cans C, NEubauer G, Bomsztyk K, et al. (2002) C-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol 22: 4535-4543.
33. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480.
34. Silva CM (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23: 8017-8023.
35. Park AYJ, Shen TL, Chien S, Guan JL (2009) Role of Focal Adhesion Kinase Ser-732 Phosphorylation in Centrosome Function during Mitosis. J Biol Chem 284: 9418-9425.
36. Park JH, Han HJ (2009) Caveolin-1 plays important role in EGF-induced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol 297: C935-C944.
37. Watson CJ, Kreuzaler PA (2009) The role of cathepsins in involution and breast cancer. J Mammary Gland Biol Neoplasia 14: 171-179.
38. Mendrysa SM, Perry ME (2000) The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol 20: 2023-2030.
39. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, et al. (2008) Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112: 1346-1356.
40. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, et al. (2009) Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101: 327-334.
41. Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9: 351-369.
42. Burger JA, Stewart DJ (2009) CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs 18: 481-490.
43. Oh JW, Olman M, Benveniste EN (2009) CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. Biol Pharm Bull 32: 573-577.
44. Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, et al. (2009) Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia 11: 333-344.
45. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, et al. (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15: 2258-2264.
46. Lindstrom AK, Tot T, Stendahl U, Syrjanen S, Syrjanen K, et al. (2009) Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer. Anticancer Res 29: 2577-2578.
47. Goetz JG, Lajoie P, Wiseman SM, Nabi IR (2008) Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27: 715-735.
48. Park JH, Han HJ (2009) Caveolin-1 plays important role in EGF-induced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol 297: C935-C944.
49. Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, Anttila S, Paakko P, et al. (2006) COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol 126: 717-724.
50. Thom I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, et al. (2009) Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res 29: 249-254.
51. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, et al. (2008) Epithelialto-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68: 2391-2399.
52. Choma DP, Milano V, Pumiglia KM, DiPersio CM (2007) Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol 127: 31-40.
53. Skorski T (2002) BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21: 8591-8604.
54. Niida H, Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis 21: 3-9.
55. Song LX, Morris M, Bagui T, Lee FY, Jove R, et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548.
56. Fabarius A, Giehl M, Rebacz B, Kraemer A, Frank O, et al. (2008) Centrosome aberrations and G(1) phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93: 1145-1154.
57. Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, et al. (2009) ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk Res 33: 1512-1519.
58. Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
59. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, et al. (2005) High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65: 11478-11485.
60. Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5: 209-217.
61. Ishizawar R, Parsons SJ (2004) C-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214.
62. Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
63. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS (2002) Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21: 974-979.
64. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
65. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, et al. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27: 469-471.
66. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
67. Giles FJ, O'Dwyer M, Swords R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23: 1698-1707.
68. Krystal GW (2001) Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 4: 16-21.
69. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, et al. (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93: 79-98.
70. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
71. Oetzel C, Jonuleit T, Gotz A, van der KH, Michels H, et al. (2000) The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 6: 1958-1968.
72. Giles FJ, O'Dwyer M, Swords R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23: 1698-1707.
73. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. pp 461-476.
74. Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
75. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932.
76. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932.
77. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283: 143-151.
78. Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18 Suppl 6: vi42-vi46.
79. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283: 143-151.
80. Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18 Suppl 6: vi42-vi46.
81. Alvarez RH, Kantarjian HM, Cortes JE (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
82. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, et al. (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116: 1582-1591.
83. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, et al. (2010) Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 28: 1387-1394.
84. Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, et al. (2004) Pyrazolo[3,4- d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem 47: 1595-1598.
85. Carraro F, Naldini A, Pucci A, Locatelli GA, Maga G, et al. (2006) Pyrazolo[3,4- d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 49: 1549-1561.
86. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, et al. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 50: 5579-5588.
87. Schenone S, Brullo C, Bruno O, Bondavalli F, Mosti L, et al. (2008) Synthesis, biological evaluation and docking studies of 4-amino substituted 1Hpyrazolo[ 3,4-d]pyrimidines. Eur J Med Chem 43: 2665-2676.
88. Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, et al. (2004) Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation. Eur J Med Chem 39: 153-160.
89. Bruno O, Brullo C, Bondavalli F, Schenone S, Ranise A, et al. (2007) Synthesis and biological evaluation of N-pyrazolyl-N9-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis. J Med Chem 50: 3618-3626.
90. Reamon-Buettner SM, Borlak J (2008) Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. Cancer Res 68: 7587-7596.
91. Niehof M, Borlak J (2005) RSK4 and PAK5 are novel candidate genes in diabetic rat kidney and brain. Mol Pharmacol 67: 604-611.
92. Rohrbeck A, Borlak J (2009) Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1. PLoS One 4: e7315. doi:10.1371/journal.pone.0007315.